BRINGING NOVEL INVESTIGATIONAL TREATMENTS FOR ECZEMA, ASTHMA and cancer ONE STEP CLOSER TO APPROVAL

Clinical trials are an important part of providing new medicines to those who need them. Learn more about each of our clinical trials below.
Zelnecirnon (RPT193) for the treatment of eczema (atopic dermatitis)

Study title:

A Phase 2 study to evaluate the efficacy and safety of zelnecirnon (RPT193) as monotherapy in adults with moderate-to-severe atopic dermatitis

About the study: This clinical trial is looking at the efficacy (change in EASI scores) and safety of different doses of an oral investigational treatment called zelnecirnon in people with moderate or severe eczema (also known as atopic dermatitis). Study participants will have either tried and failed to get adequate results with topical treatments (e.g., corticosteroids) or are not able to use topical treatments. Zelnecirnon comes as a pill and is taken by mouth once daily. Treatment will be for 16 weeks. There are approximately 50 study sites throughout the US. There is no cost to participate.

Who can participate:
  • Men and women 18–75 years of age
  • Moderate or severe eczema (atopic dermatitis)
  • Inadequate response to or unable to use topical treatments
  • Other criteria apply; learn more at the link below

EASI = eczema area and severity index.

Zelnecirnon (RPT193) for the treatment of asthma

Study title:

A Phase 2 study to evaluate the efficacy and safety of zelnecirnon (RPT193) in adults with moderate-to-severe T2-high asthma who are partially controlled on inhaled corticosteroid and long-acting beta2 agonist therapy

About the study: This clinical trial is looking at the efficacy and safety of an investigational treatment called zelnecirnon (RPT193) in people with moderate or severe T2-high asthma, which is a form of asthma that is closely associated with allergic disease. Participants will already be using an inhaled corticosteroid (ICS) and long-acting beta2 agonist (LABA). Zelnecirnon comes as a pill and is taken by mouth once daily. Treatment will be for 14 weeks. There are approximately 12 study sites throughout the US. There is no cost to participate.

Who can participate:
  • Men and women 18–65 years of age
  • Moderate or severe asthma
  • Taking an inhaled corticosteroid (ICS) combined with a long-acting beta2 agonist (LABA)
  • Other criteria apply; learn more at the link below
Tivumecirnon (FLX475) FOR THE TREATMENT OF CANCER

RAPT Therapeutics is developing a potential treatment called tivumecirnon alone and/or in combination with KEYTRUDA® (pembrolizumab).

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp.

Learn more about the study for people with various types of advanced cancers